{
    "root": "5a0ec904-251d-40f9-b35f-2b310c308af1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CELECOXIB",
    "value": "20250204",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "indications": "celecoxib capsule indicated",
    "contraindications": "\u2022 lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) \u2022 oa : 200 mg daily 100 mg twice daily . ( 2.2 , 14.1 ) \u2022 rheumatoid arthritis : 100 200 mg twice daily . ( 2.3 , 14.2 ) \u2022 jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg . ( 2.4 , 14.3 ) \u2022 : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit . ( 2.5 , 14.4 ) \u2022 ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed . ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers . ( 2.7 , 8.8 , 12.3 ) .",
    "warningsAndPrecautions": "celecoxib capsules 200 mg white white opaque hard gelatin capsules , imprinted `` cel `` cap & `` 200 mg `` body black ink supplied : ndc 72162-2357-1 : 100 capsules bottle ndc 72162-2357-5 : 500 capsules bottle storagestore room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "celecoxib capsules contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . setting cabg surgery [ ( 5.1 ) ] . patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "indications_original": "Celecoxib capsule are indicated",
    "contraindications_original": "\u2022\u00a0Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. (2.1 ) \u2022\u00a0OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) \u2022\u00a0RA: 100 to 200 mg twice daily. ( 2.3 , 14.2 ) \u2022\u00a0JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) \u2022\u00a0AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) \u2022\u00a0AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib capsules 200 mg are white to white opaque hard gelatin capsules, imprinted with \"CEL\" on cap & \"200 mg\" on body in black ink supplied as:\n                  \n                     NDC 72162-2357-1: 100 Capsules in a Bottle\n                     NDC 72162-2357-5: 500 Capsules in a Bottle\n                  \n                  StorageStore at room temperature 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Celecoxib capsules are contraindicated in the following patients:\n                  \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product\n  \n   [see\n   \n    Warnings and Precautions (5.7,\n   \n    5.9)]\n  \n   .\u00a0\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients\n  \n   [see\n   \n    Warnings and Precautions (5.7,\n   \n    5.8)]\n  \n   .\u00a0\n \n  \n                     In the setting of CABG surgery\n  \n   [see\n   \n    Warnings and Precautions (5.1)]\n  \n   .\u00a0\n \n  \n                     In patients who have demonstrated allergic-type reactions to sulfonamides\n  \n   [see\n   \n    Warnings and Precautions (5.7)]\n  \n   ."
}